Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease
- PMID: 27572953
- DOI: 10.1056/NEJMoa1607991
Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease
Abstract
Background: Limited data are available on the long-term effects of contemporary drug-eluting stents versus contemporary bare-metal stents on rates of death, myocardial infarction, repeat revascularization, and stent thrombosis and on quality of life.
Methods: We randomly assigned 9013 patients who had stable or unstable coronary artery disease to undergo percutaneous coronary intervention (PCI) with the implantation of either contemporary drug-eluting stents or bare-metal stents. In the group receiving drug-eluting stents, 96% of the patients received either everolimus- or zotarolimus-eluting stents. The primary outcome was a composite of death from any cause and nonfatal spontaneous myocardial infarction after a median of 5 years of follow-up. Secondary outcomes included repeat revascularization, stent thrombosis, and quality of life.
Results: At 6 years, the rates of the primary outcome were 16.6% in the group receiving drug-eluting stents and 17.1% in the group receiving bare-metal stents (hazard ratio, 0.98; 95% confidence interval [CI], 0.88 to 1.09; P=0.66). There were no significant between-group differences in the components of the primary outcome. The 6-year rates of any repeat revascularization were 16.5% in the group receiving drug-eluting stents and 19.8% in the group receiving bare-metal stents (hazard ratio, 0.76; 95% CI, 0.69 to 0.85; P<0.001); the rates of definite stent thrombosis were 0.8% and 1.2%, respectively (P=0.0498). Quality-of-life measures did not differ significantly between the two groups.
Conclusions: In patients undergoing PCI, there were no significant differences between those receiving drug-eluting stents and those receiving bare-metal stents in the composite outcome of death from any cause and nonfatal spontaneous myocardial infarction. Rates of repeat revascularization were lower in the group receiving drug-eluting stents. (Funded by the Norwegian Research Council and others; NORSTENT ClinicalTrials.gov number, NCT00811772 .).
Comment in
-
Balancing the Evidence Base on Coronary Stents.N Engl J Med. 2016 Sep 29;375(13):1286-8. doi: 10.1056/NEJMe1610485. Epub 2016 Aug 29. N Engl J Med. 2016. PMID: 27573082 No abstract available.
-
PCI with drug-eluting stents reduced revascularizations, but not mortality or MI, compared with bare-metal stents.Ann Intern Med. 2016 Nov 15;165(10):JC52. doi: 10.7326/ACPJC-2016-165-10-052. Ann Intern Med. 2016. PMID: 27842389 No abstract available.
-
Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.N Engl J Med. 2016 Dec 29;375(26):2604-2605. doi: 10.1056/NEJMc1613866. N Engl J Med. 2016. PMID: 28029911 No abstract available.
-
Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.N Engl J Med. 2016 Dec 29;375(26):2603-4. doi: 10.1056/NEJMc1613866. N Engl J Med. 2016. PMID: 28029912 No abstract available.
-
Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.N Engl J Med. 2016 Dec 29;375(26):2604. doi: 10.1056/NEJMc1613866. N Engl J Med. 2016. PMID: 28029913 No abstract available.
-
Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.N Engl J Med. 2016 Dec 29;375(26):2602. doi: 10.1056/NEJMc1613866. N Engl J Med. 2016. PMID: 28032958 No abstract available.
-
Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.N Engl J Med. 2016 Dec 29;375(26):2602-3. doi: 10.1056/NEJMc1613866. N Engl J Med. 2016. PMID: 28032959 No abstract available.
-
Drug-Eluting or Bare-Metal Stents for Coronary Artery Disease.N Engl J Med. 2016 Dec 29;375(26):2605. doi: 10.1056/NEJMc1613866. N Engl J Med. 2016. PMID: 28112501 No abstract available.
Similar articles
-
Long-Term outcome of drug-eluting stents compared with bare metal stents in ST-segment elevation myocardial infarction: results of the paclitaxel- or sirolimus-eluting stent versus bare metal stent in Primary Angioplasty (PASEO) Randomized Trial.Circulation. 2009 Sep 15;120(11):964-72. doi: 10.1161/CIRCULATIONAHA.108.830372. Epub 2009 Aug 31. Circulation. 2009. Retraction in: Circulation. 2010 Mar 2;121(8):e228. doi: 10.1161/CIR.0b013e3181d70edb PMID: 19720939 Retracted. Clinical Trial.
-
Everolimus-eluting stents or bypass surgery for multivessel coronary disease.N Engl J Med. 2015 Mar 26;372(13):1213-22. doi: 10.1056/NEJMoa1412168. Epub 2015 Mar 16. N Engl J Med. 2015. PMID: 25775087
-
Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.JACC Cardiovasc Interv. 2013 Aug;6(8):777-89. doi: 10.1016/j.jcin.2013.04.011. JACC Cardiovasc Interv. 2013. PMID: 23968698 Clinical Trial.
-
Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis.J Am Coll Cardiol. 2014 Feb 4;63(4):299-307. doi: 10.1016/j.jacc.2013.09.061. Epub 2013 Nov 6. J Am Coll Cardiol. 2014. PMID: 24211507 Review.
-
Long-term effect of second-generation drug-eluting stents for coronary artery disease, everolimus-eluting versus zotarolimus-eluting stents: a meta-analysis.Coron Artery Dis. 2015 May;26(3):259-65. doi: 10.1097/MCA.0000000000000222. Coron Artery Dis. 2015. PMID: 25715339 Review.
Cited by
-
Left atrial volume assessed by echocardiography identifies patients with high risk of adverse outcome after acute myocardial infarction.Echo Res Pract. 2024 Oct 21;11(1):24. doi: 10.1186/s44156-024-00060-1. Echo Res Pract. 2024. PMID: 39428485 Free PMC article.
-
Camouflaging endovascular stents with an endothelial coat using CD31 domain 1 and 2 mimetic peptides.JVS Vasc Sci. 2024 Jul 23;5:100213. doi: 10.1016/j.jvssci.2024.100213. eCollection 2024. JVS Vasc Sci. 2024. PMID: 39257386 Free PMC article.
-
The association between stent type and developing angina pectoris following percutaneous coronary intervention.BMC Cardiovasc Disord. 2024 Sep 2;24(1):466. doi: 10.1186/s12872-024-04116-2. BMC Cardiovasc Disord. 2024. PMID: 39218866 Free PMC article.
-
Identification of endothelial protein C receptor as a novel druggable agonistic target for reendothelialization promotion and thrombosis prevention of eluting stent.Bioact Mater. 2024 Aug 9;41:485-498. doi: 10.1016/j.bioactmat.2024.07.028. eCollection 2024 Nov. Bioact Mater. 2024. PMID: 39210965 Free PMC article.
-
Interventions to Facilitate Shared Decision-Making Using Decision Aids with Coronary Heart Disease Patients: Systematic Review and Meta-Analysis.Rev Cardiovasc Med. 2023 Aug 25;24(8):246. doi: 10.31083/j.rcm2408246. eCollection 2023 Aug. Rev Cardiovasc Med. 2023. PMID: 39076712 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous